Merck & Co., Inc. (NYSE:MRK) Shares Sold by Unigestion Holding SA

Unigestion Holding SA reduced its holdings in Merck & Co., Inc. (NYSE:MRK) by 3.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 116,765 shares of the company’s stock after selling 4,570 shares during the quarter. Unigestion Holding SA’s holdings in Merck & Co., Inc. were worth $8,766,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in MRK. Amundi acquired a new position in Merck & Co., Inc. in the second quarter valued at $784,989,000. Barrow Hanley Mewhinney & Strauss LLC increased its stake in Merck & Co., Inc. by 1,324.3% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 10,145,652 shares of the company’s stock valued at $789,028,000 after purchasing an additional 9,433,323 shares during the last quarter. LSV Asset Management increased its stake in Merck & Co., Inc. by 47.8% in the second quarter. LSV Asset Management now owns 14,306,091 shares of the company’s stock valued at $1,112,584,000 after purchasing an additional 4,628,832 shares during the last quarter. FMR LLC increased its stake in Merck & Co., Inc. by 67.3% in the second quarter. FMR LLC now owns 10,357,873 shares of the company’s stock valued at $805,532,000 after purchasing an additional 4,165,565 shares during the last quarter. Finally, Morgan Stanley increased its stake in Merck & Co., Inc. by 17.1% in the second quarter. Morgan Stanley now owns 26,289,496 shares of the company’s stock valued at $2,044,534,000 after purchasing an additional 3,832,086 shares during the last quarter. Hedge funds and other institutional investors own 71.79% of the company’s stock.

In other news, CFO Caroline Litchfield sold 18,335 shares of the stock in a transaction that occurred on Thursday, November 4th. The stock was sold at an average price of $91.00, for a total transaction of $1,668,485.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Richard R. Deluca sold 29,782 shares of the stock in a transaction that occurred on Thursday, November 4th. The stock was sold at an average price of $90.40, for a total value of $2,692,292.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 936,784 shares of company stock worth $78,682,559. 0.32% of the stock is currently owned by company insiders.

MRK traded down $0.52 on Thursday, reaching $82.28. The company’s stock had a trading volume of 8,534,741 shares, compared to its average volume of 12,415,974. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.31 and a quick ratio of 1.07. The business’s 50 day moving average is $80.47 and its 200 day moving average is $78.04. Merck & Co., Inc. has a 1 year low of $70.89 and a 1 year high of $91.40. The stock has a market cap of $207.83 billion, a price-to-earnings ratio of 29.07, a price-to-earnings-growth ratio of 2.11 and a beta of 0.46.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Wednesday, October 27th. The company reported $1.75 EPS for the quarter, topping analysts’ consensus estimates of $1.55 by $0.20. Merck & Co., Inc. had a return on equity of 48.21% and a net margin of 14.64%. The company had revenue of $13.15 billion for the quarter, compared to the consensus estimate of $12.32 billion. During the same quarter last year, the business posted $1.74 EPS. Merck & Co., Inc.’s quarterly revenue was up 4.8% compared to the same quarter last year. As a group, research analysts forecast that Merck & Co., Inc. will post 5.76 earnings per share for the current fiscal year.

MRK has been the subject of several research analyst reports. Mizuho initiated coverage on Merck & Co., Inc. in a research note on Thursday, October 28th. They set a “buy” rating and a $99.00 price target for the company. Argus upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $110.00 price target for the company in a research note on Monday, November 1st. Berenberg Bank restated a “hold” rating and set a $92.00 price target (up from $86.00) on shares of Merck & Co., Inc. in a research note on Sunday, October 10th. Barclays upped their price target on Merck & Co., Inc. from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Monday, November 1st. Finally, Truist upped their price target on Merck & Co., Inc. from $92.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $95.73.

Merck & Co., Inc. Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also: After-Hours Trading

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.